Statins in patients with chronic kidney disease-an attempt at recommendations

Current Medical Research and Opinion

Volumn 29, Issue 11, 2013, Pages 1419-1422

  Banach, MacIej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dyslipidaemia; Statins

Indexed keywords

APOLIPOPROTEIN B; CREATININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIALYSIS; ELECTROLYTE DISTURBANCE; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MONOTHERAPY; MORTALITY; OBESITY; OXIDATIVE STRESS; PRIMARY PREVENTION; PROTEIN URINE LEVEL; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84885730680     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.833502     Document Type: Review

References (32)

1. Gluba A, Mikhailidis DP, Lip GY, et al. Metabolic syndrome and renal disease. Int J Cardiol 2013;164:141-50
2. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-66 (Pubitemid 46094690)
3. Franczyk-Skó ra B, Gluba A, Banach M, et al. Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol 2012;13:162
4. Muntner P, He J, Astor BC, et al. Traditional and non-traditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38 (Pubitemid 41725151)
5. Nannayakkara PWB, van Guldener C, ter Wee PM, et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007;167:1262-70 (Pubitemid 46998497)
6. Nikolic D, Nikfar S, Salari P, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013;29:435-51
7. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002;39:283-90 (Pubitemid 34174250)
8. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-70 (Pubitemid 36278373)
9. Athyros VG, Hatzitolios AI, Karagiannis A, et al.; IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92
10. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
11. Barylski M, Nikfar S, Mikhailidis DP, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:35-44
12. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14: 2084-91 (Pubitemid 36909916)
13. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother 2010;11: 2665-74
14. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
15. Rocco MV, Berns JS. KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-86
16. Barylski M, Mayszko J, Rysz J, et al. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 2011;7:1055-66
17. Tonelli M. Statins for slowing kidney disease progression: an as yet unproven indication. Am J Kidney Dis 2008;52:391-4
18. Wanner C, Krane V, Mä rz W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48 (Pubitemid 41058323)
19. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360: 1395-407
20. Baigent C, Landray MJ, Reith C et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011;377:2181-92
21. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, et al. Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate. Arch Med Sci 2011;7:658-64
22. Banach M, Hering D, Narkiewicz K, et al. Lipids, blood pressure, kidney-what was new in 2012? Int J Pharmacol 2012;8:659-78
23. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75
24. Banach M, Nikfar S, Rahimi R, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects-a meta-analysis of randomized controlled trials. Int J Cardiol 2013;doi:10.1016/j.ijcard.2013.03.068. [Epub ahead of print]
25. Banach M, Nikolic D, Nikfar S, et al. Renal outcomes of use of statins in chronic kidney disease patients: A meta-analysis of randomized controlled trials. 81st European Atherosclerosis Society Congress, 2-5 June 2013, Lyon, France. Moderated Poster Session C, Poster No. 1410
26. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, et al.; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217(Suppl 1):S1-44
27. Anderson TJ, Gré goire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-67
28. An International Atherosclerosis Society (IAS) Position Paper: Global Recommendations for the Management of Dyslipidemia. Updated 25 July 2013. Available at: http://www.athero.org/IASPositionPaper.asp [last accessed on 2 Aug 2013]
29. Bao YS, Na SP, Jia XB, et al. Prevalence and risk factors for chronic kidney disease in patients with coronary artery disease. Curr Med Res Opin 2012;28:379-84
30. Couser WG, Riella MC. World Kidney Day 2011-protect your kidneys, save your heart. Arch Med Sci 2011;7:1-4
31. Athyros VG, Karagiannis A, Ganotakis ES, et al.; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
32. Olechnowicz-Tietz S, Gluba A, Paradowska A, et al. The risk of atherosclerosis in patients with chronic kidney disease. Int Urol Nephrol 2013; doi: 0.1007/s11255-013-0407-1. [Epub ahead of print]